Severity
Moderate
CPSC recall · Reported January 31, 2013
These child-resistant caps can fail to function properly and enable the cap to be removed by a child with the tamper-evident seal in place, posing a risk of unintentional ingestio…
Novartis Consumer Health Inc., of Parsippany, Nj recalled This recall involves Triaminic® Syrups and Theraflu Warming Relief® Syrups for coughs, co… - a moderate-severity action.
Triaminic and Theraflu Products Recalled Due to Failure to Meet Child-Resistant Closure R… was recalled by Novartis Consumer Health Inc., of Parsippany, Nj in January 31, 2013. Reason: These child-resistant caps can fail to function properly and enable the cap to be removed by a child with the…. Remedy: Consumers should immediately stop using the recalled product and contact Novartis for ins…. Verify recall #13114 with the CPSC before acting.
The recall
Novartis Consumer Health Inc., of Parsippany, Nj issued this moderate-severity CPSC recall-These child-resistant caps can fail to function properly and enable the cap to be removed by a child with the….
Sourced from official CPSC enforcement records. Verify recall #13114 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This CPSC action (record #13114) was formally reported on January 31, 2013. It is classified under Moderate severity, with a current status of Active. Novartis Consumer Health Inc., of Parsippany, Nj is listed as the recalling firm. Federal records list the affected scope as About 2.3 Million.
The documented reason for this recall is: These child-resistant caps can fail to function properly and enable the cap to be removed by a child with the tamper-evident seal in place, posing a risk of unintentional ingestion and poisoning. These products contain … Distribution information was not included in the agency filing, so consumers should assume broad potential exposure until the firm publishes point-of-sale details. The remedy documented by the agency is: Consumers should immediately stop using the recalled product and contact Novartis for instructions on how to return the product for a full refund. - consumers holding this product should act on that instruction rather than relying on general guidance.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
About 2.3 Million
Related Recalls
6
0 from same agency
This recall involves Triaminic® Syrups and Theraflu Warming Relief® Syrups for coughs, colds and fevers. There are 24 types of these two products included in the recall. A complete list of products, lot numbers and National Drug Codes (NDC) can be found at www.novartisOTC.com. Lot numbers are located on the bottom panel of the box and on the left side of the label on the bottle. The NDC number is located on the upper right corner of the front panel of the Triaminic Syrups box and the upper left corner of the Theraflu Warming Relief Syrups bottle.
These child-resistant caps can fail to function properly and enable the cap to be removed by a child with the tamper-evident seal in place, posing a risk of unintentional ingestion and poisoning. These products contain acetaminophen and diphenhydramine which are required by the Poison Prevention Packaging Act to be sealed with child-resistant packaging.
Consumers should immediately stop using the recalled product and contact Novartis for instructions on how to return the product for a full refund.
| Attribute | Value |
|---|---|
| Agency | U.S. Consumer Product Safety Commission |
| Severity class | Moderate |
| Status | Active |
| Recall number | 13114 |
| Date reported | January 31, 2013 |
| Date initiated | January 31, 2013 |
| Recalling firm | Novartis Consumer Health Inc., of Parsippany, Nj |
| Affected scope | About 2.3 Million |
| Distribution | Not disclosed |
| Official source | CPSC notice → |
Profile values are sourced directly from the official CPSC enforcement record. Source: U.S. Consumer Product Safety Commission.
What to do with this recall
Consumers should immediately stop using the recalled product and contact Novartis for instructions on how to return the product f…
This page summarizes the official CPSC record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: CPSC, reported January 31, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.